Antidotes for novel oral anticoagulants: Current status and future potential

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 8, 2015, Pages 1736-1745

  Crowther, Mark A ^a,b  

^a WORCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

^b ST JOSEPH S HOSPITAL   (Canada)

Author keywords

anticoagulants; apixaban; dabigatran; factor VIIa; hemorrhage; prothrombin complex concentrate; rivaroxaban

Indexed keywords

ACTIVATED CARBON; ACTIVATED PROTHROMBIN COMPLEX; ANDEXANET ALFA; ANTICOAGULANT AGENT; ANTIDOTE; APIXABAN; CIRAPARANTAG; DABIGATRAN; EDOXABAN; IDARUCIZUMAB; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; WARFARIN; ARGININE; COAGULATING AGENT; MONOCLONAL ANTIBODY; PIPERAZINE DERIVATIVE;

AIRWAY; ANTICOAGULATION; ARTICLE; BREATHING; CIRCULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DETERMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; HEMODIALYSIS; HUMAN; KIDNEY CLEARANCE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; BLOOD CLOTTING; CHEMICALLY INDUCED; DRUG EFFECTS; HEMORRHAGE; ORAL DRUG ADMINISTRATION; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTICOAGULANTS; ANTIDOTES; ARGININE; BLOOD COAGULATION; COAGULANTS; HEMORRHAGE; HUMANS; PIPERAZINES; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84938118124     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.303402     Document Type: Article

References (52)

1. Makris M, Van Veen JJ, Tait CR, Mumford AD, Laffan M, British Committee for Standards in Haematology Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haematol 2013 160 35 46. doi: 10.1111/bjh.12107
2. Makris M, Greaves M, Phillips WS, Kitchen S, Rosendaal FR, Preston EF., Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997 77 477 480
3. Makris M, Van Veen JJ., Three or four factor prothrombin complex concentrate for emergency anticoagulation reversal? Blood Transfus 2011 9 117 119. doi: 10.2450/2011.0111-10
4. Rosovsky RP, Crowther MA., What is the evidence for the off-label use of recombinant factor VIIa (rFVIIa) in the acute reversal of warfarin? ASH Education Book 2008 2008 36 38
5. Watson HG, Baglin T, Laidlaw SL, Makris M, Preston FE., A comparison of the efficacy and rate of response to oral and intravenous Vitamin K in reversal of over-Anticoagulation with warfarin. Br J Haematol 2001 115 145 149
6. Electronic Medicines Compendium. eMC Web Site. http://www.medicine.org.uk/. Accessed March 20, 2014
7. Pernod G, Albaladejo P, Godier A, Working Group on Perioperative Haemostasis Management of major bleeding complications and emergency surgery in patients on long-Term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP)-March 2013. Arch Cardiovasc Dis 2013 106 382 393. doi: 10.1016/j.acvd.2013.04.009
8. Gosselin R, Hawes E, Moll S, Adcock D., Performance of various laboratory assays in the measurement of dabigatran in patients receiving therapeutic doses: a prospective study based on peak and trough plasma levels. Am J Clin Pathol 2014 141 262 267. doi: 10.1309/AJCPRNUMI4PVSJ7Q
9. Lindahl TL, Baghaei F, Blixter IF, Gustafsson KM, Stigendal L, Sten-Linder M, Strandberg K, Hillarp A, Expert Group on Coagulation of the External Quality Assurance in Laboratory Medicine in Sweden Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011 105 371 378. doi: 10.1160/TH10-06-0342
10. Douxfils J, Chatelain C, Chatelain B, Dogné JM, Mullier F., Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost 2013 110 283 294. doi: 10.1160/TH12-12-0898
11. Samama MM, Contant G, Spiro TE, Perzborn E, Guinet C, Gourmelin Y, Le Flem L, Rohde G, Martinoli JL, Rivaroxaban Anti-Factor Xa Chromogenic Assay Field Trial Laboratories Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012 107 379 387. doi: 10.1160/TH11-06-0391
12. Hillarp A, Baghaei F, Fagerberg Blixter I, Gustafsson KM, Stigendal L, Sten-Linder M, Strandberg K, Lindahl TL., Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011 9 133 139. doi: 10.1111/j.1538-7836.2010.04098.x
13. Morishima Y, Kamisato C., Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay. Am J Clin Pathol 2015 143 241 247. doi: 10.1309/AJCPQ2NJD3PXFTUG
14. Kitchen S., UK NEQAS for Blood Coagulation Surveys with Oral Direct Inhibitors/New Oral Anticoagulants 2014 Sheffield, UK NEQAS
15. van Ryn J, Sieger P, Kink-Eiband M, Gansser D, Clemens A., Adsorbtion of dabigatran etexilate in water or dabigatran in pooled human plasma by activated charcoal in vitro. Blood 2009 114 1065
16. Stangier J, Rathgen K, Stähle H, Mazur D., Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010 49 259 268. doi: 10.2165/11318170-000000000-00000
17. Singh T, Maw TT, Henry BL, Pastor-Soler NM, Unruh ML, Hallows KR, Nolin TD., Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience. Clin J Am Soc Nephrol 2013 8 1533 1539. doi: 10.2215/CJN.01570213
18. Schiele F, van Ryn J, Canada K, Newsome C, Sepulveda E, Park J, Nar H, Litzenburger T., A specific antidote for dabigatran: functional and structural characterization. Blood 2013 121 3554 3562. doi: 10.1182/blood-2012-11-468207
19. Grottke O, van Ryn J, Spronk HM, Rossaint R., Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model. Crit Care 2014 18 R27. doi: 10.1186/cc13717
20. Glund S, Stangier J, Schmohl M, De Smet M, Gansser D, Lang B, Moschetti V, Ramael S, Reilly P., A Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Healthy Male Volunteers. Circulation 2013 128 A17765
21. van Ryn J, Schmoll M, Pillu H, Gheyle L, Brys J, Moschetti V, Glund S, Reilly P, Stangier J., Effect of Dabigatran on the ability to generate fibrin at a wound site and its reversal by Idatucizumab, the antedote to Dabigatran, in Healthy Volunteers: An Exploratory Marker of Blood Loss. Circulation 2014 130 A18403
22. Glund S, Stangier J, Schmohl M, Moschetti V, Haazen W, Gansser M, Norris S, Lang B, Reilly P., Idarucizumab, a Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Elderly and Renally Impaired Subjects. Blood 2014 124 A344
23. Blum J, Carreiro S, Hack JB., Intravenous lipid emulsion does not reverse dabigatran-induced anticoagulation in a rat model. Acad Emerg Med 2013 20 1022 1025. doi: 10.1111/acem.12225
24. Pragst I, Zeitler SH, Doerr B, Kaspereit FJ, Herzog E, Dickneite G, van Ryn J., Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost 2012 10 1841 1848. doi: 10.1111/j.1538-7836.2012.04859.x
25. Lambourne MD, Eltringham-Smith LJ, Gataiance S, Arnold DM, Crowther MA, Sheffield WP., Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate. J Thromb Haemost 2012 10 1830 1840. doi: 10.1111/j.1538-7836.2012.04863.x
26. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M., Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011 124 1573 1579. doi: 10.1161/CIRCULATIONAHA.111.029017
27. Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Crackowski JL, Pernod G., Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012 108 217 224. doi: 10.1160/TH12-03-0179
28. Herrmann R, Thom J, Wood A, Phillips M, Muhammad S, Baker R., Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban. Thromb Haemost 2014 111 989 995. doi: 10.1160/TH13-07-0607
29. Khoo TL, Weatherburn C, Kershaw G, Reddel CJ, Curnow J, Dunkley S., The use of FEIBA® in the correction of coagulation abnormalities induced by dabigatran. Int J Lab Hematol 2013 35 222 224. doi: 10.1111/ijlh.12005
30. van Ryn J, Ruehl D, Priepki H, Hauel N, Wienen W., Reversability of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran by recombinant facotr VIIa or activated prothrombin complex concentrate. Haematologica 2008 93 A0370
31. Escolar G, Fernandez-Gallego V, Arellano-Rodrigo E, Roquer J, Reverter JC, Sanz VV, Molina P, Lopez-Vilchez I, Diaz-Ricart M, Galan AM., Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood. PLoS One 2013 8 e78696. doi: 10.1371/journal.pone.0078696
32. Martin AC, Le Bonniec B, Fischer AM, Marchand-Leroux C, Gaussem P, Samama CM, Godier A., Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis. Int J Cardiol 2013 168 4228 4233. doi: 10.1016/j.ijcard.2013.07.152
33. Perzborn E, Heitmeier S, Laux V, Buchmüller A., Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro. Thromb Res 2014 133 671 681. doi: 10.1016/j.thromres.2014.01.017
34. Körber MK, Langer E, Ziemer S, Perzborn E, Gericke C, Heymann Cv., Measurement and reversal of prophylactic and therapeutic peak levels of rivaroxaban: an in vitro study. Clin Appl Thromb Hemost 2014 20 735 740. doi: 10.1177/1076029613494468
35. Dinkelaar J, Molenaar PJ, Ninivaggi M, de Laat B, Brinkman HJ, Leyte A., In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for Rivaroxaban. J Thromb Haemost 2013 11 1111 1118. doi: 10.1111/jth.12236
36. Perzborn E, Gruber A, Tinel H, Marzec UM, Buetehorn U, Buchmueller A, Heitmeier S, Laux V., Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. Thromb Haemost 2013 110 162 172. doi: 10.1160/TH12-12-0907
37. Levi M, Moore KT, Castillejos CF, Kubitza D, Berkowitz SD, Goldhaber SZ, Raghoebar M, Patel MR, Weitz JI, Levy JH., Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost 2014 12 1428 1436. doi: 10.1111/jth.12599
38. Zahir H, Brown KS, Vandell AG, Desai M, Maa JF, Dishy V, Lomeli B, Feussner A, Feng W, He L, Grosso MA, Lanz HJ, Antman EM., Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation 2015 131 82 90. doi: 10.1161/CIRCULATIONAHA.114.013445
39. Halim A, MM S, Mendell J., Ex vivo reversal of the anticoagulant effect of edoxaban. Thromb Res 2014 134 909 913
40. Perzborn E, Harwardt M., Recombinant factor VIIa partially reverses the effects of the factor Xa inhibitor rivaroxaban on thrombin generation, but not the effects of thrombin inhibitors, in vitro. J Thromb Haemost 2007 5 P-W-640
41. Dumkow LE, Voss JR, Peters M, Jennings DL., Reversal of dabigatran-induced bleeding with a prothrombin complex concentrate and fresh frozen plasma. Am J Health Syst Pharm 2012 69 1646 1650. doi: 10.2146/ajhp120055
42. Dager WE, Gosselin RC, Roberts AJ., Reversing dabigatran in life-Threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity. Crit Care Med 2013 41 e42 e46. doi: 10.1097/CCM.0b013e31827caaa3
43. Hsia CC, Chin-Yee IH, McAlister VC., Use of recombinant activated factor VII in patients without hemophilia: a meta-Analysis of randomized control trials. Ann Surg 2008 248 61 68. doi: 10.1097/SLA.0b013e318176c4ec
44. Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, Luan P, Hutchaleelaha A, Inagaki M, Conley PB, Phillips DR, Sinha U., A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013 19 446 451. doi: 10.1038/nm.3102
45. Crowther M, Vandana M, Michael K, A Phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for Fxa inhibitors. Blood 2013 122 A3636
46. Crowther M, Levy G, Lu G, Leeds J, Barron L, Conley P, Castillo J, Curnutte J, Connolly S., ANNEXA-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial, Demonstrating Reversal of Apixaban-Induced Anticoagulation in Older Subjects by Andexanet alpha (PRT064445), a Universal Antidote for Factor Xa (fXa) Inhibitors. Circulation 2014 130 2116 2117
47. Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso M, Brown K, Dishy V, Noveck RJ, Costin JC., Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med 2014 371 2141 2142. doi: 10.1056/NEJMc1411800
48. Laulicht B, Bakhru S, Lee C, Baker C, Jiang X, Mathiowitz E, Costin J, Steiner S., Small Molecule Antidote for Anticoagulants. Circulation 2012 126 A11395
49. Bakhru S, Laulicht B, Jiang X, Chen L, Pan D, Grosso M, Morishima Y, Brown K, Masumoto H, Costin J, Steiner S., A synthetic small molecule which reverses over-dosage and bleeding by the new oral anticoagulants. Circulation 2013 128 A18809
50. Hollenbach S, Lu G, DeGuzman F, Tan S, Pratikhya P, Pandey A, Conley P, Curnutte J., Andexanet-Alfa and PER977 (Arapazine) Correct Blood Loss in a Rabbit Liver Laceration Model-Only Andexanet Reverses Markers of fXa-mediated Anticoagulation. Circulation 2014 130 A14657
51. Lu G, Kotha J, Cardenas J, Herr M, Pandey A, Curnutte J, Conley P, Jennings L., In vitro characterization of andexanet alfa (PRT064445), a specific fXa inhibitor antidote versus aripazine (PER977), a non-specific reversal agent. Circulation 2014 130 A18218
52. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM., Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-Analysis of randomised trials. Lancet 2014 383 955 962. doi: 10.1016/S0140-6736(13)62343-0